These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4269352)

  • 1. [Immunologic studies in sclerodermia].
    Jablonska S; Chorzelski T
    Allerg Immunol (Leipz); 1972; 18(3):187-90. PubMed ID: 4269352
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunofluorescent studies in patients with scleroderma and in their families].
    Szczepański A
    Przegl Dermatol; 1972; 59(6):727-32. PubMed ID: 4566145
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antinuclear antibodies in mesenchymal scleroderma and progressive systemic sclerosis (author's transl)].
    Sugiura M; Hashimoto T; Kurihara S; Nishikawa T; Hatano H
    Nihon Hifuka Gakkai Zasshi; 1980 Sep; 90(10):935-7. PubMed ID: 7012401
    [No Abstract]   [Full Text] [Related]  

  • 4. Antinuclear antibodies in localized scleroderma.
    Takehara K; Moroi Y; Nakabayashi Y; Ishibashi Y
    Arthritis Rheum; 1983 May; 26(5):612-6. PubMed ID: 6405756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Demonstration of antinuclear factors using indirect immunofluorescence in scleroderma patients].
    Nebe H; Blume N
    Dermatol Monatsschr; 1971 Jan; 157(1):27-31. PubMed ID: 4938251
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies.
    Cassani F; Tosti A; Bianchi FB; Fusconi M; Selleri L; Baffoni L; Veronesi S; Volta U; Lenzi M; Pisi E
    Clin Exp Rheumatol; 1987; 5(1):23-8. PubMed ID: 3109797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antinuclear autoantibodies in systemic diseases].
    Butov IuS
    Vestn Dermatol Venerol; 1980 Nov; (11):17-22. PubMed ID: 7003977
    [No Abstract]   [Full Text] [Related]  

  • 8. [Association of HLA antigens with scleroderma].
    Kühnl P; Schütz K; Altmeyer P; Holzmann H; Seidl S
    Z Hautkr; 1985 Jun; 60(11):866-8. PubMed ID: 3892952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of anti-centromere antibodies. Clinical value].
    Meyer O; Haim T; Ryckewaert A
    Rev Rhum Mal Osteoartic; 1983 Apr; 50(4):261-6. PubMed ID: 6348931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radiochemical demonstration of serum antibodies against double stranded DNA in progressive and circumscribed scleroderma].
    Meffert H; Falck P; Sönnichsen N
    Dermatol Wochenschr; 1975 Sep; 161(9):771-2. PubMed ID: 1081055
    [No Abstract]   [Full Text] [Related]  

  • 11. [Differentiation with immunofluorescence of complement fixing and non-fixing antinuclear factors in patients with and without disseminated lupus erythematosus].
    Peltier AP
    Pathol Biol; 1968 Apr; 16(7):439-44. PubMed ID: 4882383
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anti-DNA antibodies; results of a new method of detection using the fluorescent antibody technic].
    Kahn MF; Peltier AP; Haim T; Marcheteau M; de Sèze S
    Rev Rhum Mal Osteoartic; 1973 Jun; 40(6):393-8. PubMed ID: 4580290
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantitative studies of immunofluorescent staining. VI. Defined complement immunofluorescent staining for antinuclear antibodies in systemic lupus and other collagen diseases.
    Diaz Gill GA; Beutner EH; Eisenberg RB
    Int Arch Allergy Appl Immunol; 1973; 45(6):868-79. PubMed ID: 4586867
    [No Abstract]   [Full Text] [Related]  

  • 14. [Scleroderma in children (author's transl)].
    Posternak F; Orusco M
    Schweiz Rundsch Med Prax; 1974 Jul; 63(30):913-21. PubMed ID: 4547092
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical relevance of immunologic findings in scleroderma.
    Jablonska S; Blaszczyk M; Chorzelski TP; Jarzabek-Chorzelska M; Kumar V; Beutner EH
    Clin Dermatol; 1992; 10(4):407-21. PubMed ID: 1303806
    [No Abstract]   [Full Text] [Related]  

  • 16. [Significance of antinuclear antibodies in overlap syndromes. I. Relationship between systemic lupus erythematosus, diffuse scleroderma and dermatomyositis].
    Zitnan D; Rovenský J; Cebecauer L; Hajzok O
    Fysiatr Revmatol Vestn; 1973 Jun; 51(3):152-7. PubMed ID: 4592583
    [No Abstract]   [Full Text] [Related]  

  • 17. Localized scleroderma-like lesions induced by the Köbner phenomenon in a patient with systemic sclerosis positive for anticentromere antibody.
    Asano Y; Sato S
    Eur J Dermatol; 2020 Aug; 30(4):431-432. PubMed ID: 32808595
    [No Abstract]   [Full Text] [Related]  

  • 18. [Behavior of antinuclear factors in the scleroderma].
    Barthelmes H
    Dermatol Monatsschr; 1975 Jul; 161(7):536-44. PubMed ID: 1081957
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antinuclear, anti-DNA and anti-lymphocyte antibodies in systemic scleroderma. 62 cases].
    Dourdan P; Labro MT; Bourgeois P; Vinceneux P; Elias I; Kaplan G; Kahn MF
    Rev Rhum Mal Osteoartic; 1983 Jun; 50(7):521-4. PubMed ID: 6604306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antinuclear antibodies in localized scleroderma].
    Takehara K; Nakabayashi Y; Ishibashi Y; Moroi Y
    Nihon Hifuka Gakkai Zasshi; 1982; 92(8):883-8. PubMed ID: 6816966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.